FY Ending January 2026 Earnings Presentation

FY Ending January 2026 Earnings Report

In the consolidated income statement for the fiscal year ending January 2026, research and development expenses amounted to 2,678 million JPY (Year-over-Year +321 million JPY), and business expenses were 3,794 million JPY (Year-over-Year +278 million JPY). Operating income was a loss of 3,794 million JPY, and net income was a loss of 3,842 million JPY, both declining compared to the prior year. On the consolidated balance sheet, approximately 16.2 billion JPY in growth capital was secured through new share issuance and other means, resulting in a significant increase in cash and deposits to 15,083 million JPY. Total assets reached 15,621 million JPY, and total net assets stood at 13,604 million JPY.

Earnings Guidance and Growth Strategy for the Current Fiscal Year

For the fiscal year ending January 2027, earnings guidance projects research and development expenses of 4,110 million JPY, business expenses of 5,625 million JPY, operating income as a loss of 5,625 million JPY, and net income as a loss of 5,635 million JPY. Although continued losses are forecasted, recording of business revenue is anticipated following the drug price listing of Akugo®. As cornerstones of the growth strategy, SanBio aims to establish Japan as its mother base, realize its U.S. operations, and achieve success with its stroke treatment drug, targeting global leadership in regenerative medicine. Marketing and public relations activities, as well as patient support systems, are being further developed.